Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience Corp (NASDAQ:TWST), sold 1,962 shares of the company’s common stock on May 4, 2026. The shares were sold at a price of $57.1488 per share, for a total value of $112,125.
Following this transaction, Mr. Cho directly holds 135,941 shares of Twist Bioscience common stock. The sale represents shares required to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer’s election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" arrangement and do not represent discretionary trades by Mr. Cho.
In other recent news, Twist Bioscience Corporation reported its Q2 FY2026 earnings, highlighting significant developments for investors. The company achieved total revenues of $111 million, marking a 19% year-over-year growth and surpassing the consensus estimate of $108 million. Despite this revenue success, Twist Bioscience reported an earnings per share (EPS) of -$0.71, which fell short of the forecasted -$0.48. This earnings miss did not deter investor optimism, as reflected in a rise in the company’s stock during pre-market trading.
Additionally, TD Cowen raised its price target for Twist Bioscience stock from $58 to $68, maintaining a Buy rating. The firm attributed this adjustment to the company’s revenue beat, which it viewed positively. These recent developments indicate a mixed financial performance for Twist Bioscience, with strong revenue growth contrasting with the EPS miss.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what TWST is really worth.Get instant clarity on TWST—plus thousands of other stocks—before the opportunity disappears.